Lexicon Pharmaceuticals, Inc. (LXRX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 21.1M | 5.49M | 14.18M | 28.87M | 1.26M | 26.55M | 1.75M | 1.65M | 1.13M | 702K | 162K | 317K |
| Revenue Growth % | 1572.11% | -79.31% | 710.4% | 1652.64% | 11.68% | 3682.62% | 980.25% | 419.56% | 4608.33% | 2407.14% | 315.38% | 805.71% |
| Cost of Goods Sold | 108K | 319K | 10K | 209K | 30K | 25.93M | 71K | 166K | 175K | 14.83M | 7K | 8K |
| COGS % of Revenue | 0.51% | 5.81% | 0.07% | 0.72% | 2.38% | 97.66% | 4.06% | 10.08% | 15.49% | 2112.82% | 4.32% | 2.52% |
| Gross Profit | 20.99M | 5.17M | 14.17M | 28.66M | 1.23M | 621K | 1.68M | 1.48M | 955K | -14.13M | 155K | 309K |
| Gross Margin % | 99.49% | 94.19% | 99.93% | 99.28% | 97.62% | 2.34% | 95.94% | 89.92% | 84.51% | -2012.82% | 95.68% | 97.48% |
| Gross Profit Growth % | 1604.06% | 733.17% | 744.07% | 1834.98% | 29.01% | 104.39% | 983.23% | 379.29% | 3879.17% | -18740% | 297.44% | 782.86% |
| Operating Expenses | 21.99M | 19.95M | 26.36M | 24.92M | 26.91M | 33.36M | 65.37M | 56.84M | 46.29M | 32.61M | 49.79M | 44.55M |
| OpEx % of Revenue | 104.21% | 363.26% | 185.86% | 86.33% | 2132.41% | 125.62% | 3735.54% | 3450.82% | 4096.28% | 4644.87% | 30732.1% | 14053.31% |
| Selling, General & Admin | 9.23M | 8.76M | 7.6M | 9.35M | 11.61M | 0 | 39.59M | 39.19M | 32.06M | 0 | 32.23M | 30.01M |
| SG&A % of Revenue | 43.76% | 159.42% | 53.6% | 32.39% | 919.81% | - | 2262.4% | 2379.6% | 2837.17% | - | 19893.83% | 9466.25% |
| Research & Development | 12.76M | 11.2M | 18.76M | 15.57M | 15.3M | 26.68M | 25.78M | 17.64M | 14.23M | 14.76M | 17.56M | 14.54M |
| R&D % of Revenue | 60.45% | 203.84% | 132.26% | 53.94% | 1212.6% | 100.49% | 1473.14% | 1071.22% | 1259.12% | 2102.85% | 10838.27% | 4587.07% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 1000K | 0 | 0 | 0 | 1000K | 0 | 0 |
| Operating Income | -996K | -14.78M | -12.19M | 3.74M | -25.68M | -32.74M | -63.69M | -55.35M | -45.33M | -46.74M | -49.63M | -44.24M |
| Operating Margin % | -4.72% | -269.07% | -85.93% | 12.94% | -2034.79% | -123.28% | -3639.6% | -3360.9% | -4011.77% | -6657.69% | -30636.42% | -13955.84% |
| Operating Income Growth % | 96.12% | 54.85% | 80.87% | 106.75% | 43.35% | 29.95% | -28.33% | -25.12% | -45.57% | -54.36% | -114.9% | -84.28% |
| EBITDA | -996K | -14.66M | -12.04M | 3.91M | -25.5M | -32.61M | -63.57M | -55.22M | -45.19M | -46.59M | -49.48M | -44.1M |
| EBITDA Margin % | -4.72% | -266.92% | -84.87% | 13.55% | -2020.84% | -122.81% | -3632.4% | -3352.46% | -3999.03% | -6636.75% | -30543.21% | -13910.41% |
| EBITDA Growth % | 96.09% | 55.04% | 81.07% | 107.09% | 43.56% | 30% | -28.47% | -25.22% | -45.63% | -54.4% | -115.25% | -84.5% |
| D&A (Non-Cash Add-back) | 0 | 118K | 151K | 176K | 176K | 125K | 126K | 139K | 144K | 147K | 151K | 144K |
| EBIT | -996K | -14.78M | -10.61M | 5.57M | -23.46M | -20.44M | -60.25M | -51.22M | -44.6M | -45.3M | -46.63M | -42.94M |
| Net Interest Income | 1.59M | -750K | -582K | -484K | 384K | -1.03M | -1.12M | 1.93M | -3.06M | -3.02M | -894K | -664K |
| Interest Income | 0 | 1.28M | 1.57M | 1.83M | 2.22M | 2.83M | 3.44M | 4.14M | 1.88M | 2.4M | 3M | 1.3M |
| Interest Expense | -1.59M | 2.03M | 2.15M | 2.32M | 1.83M | 3.86M | 4.56M | 2.21M | 4.95M | 5.42M | 3.9M | 1.96M |
| Other Income/Expense | -47K | -750K | -582K | -484K | 384K | -1.03M | -1.12M | 1.93M | -3.06M | -3.02M | -894K | -664K |
| Pretax Income | -1.04M | -15.53M | -12.77M | 3.25M | -25.3M | -33.77M | -64.81M | -53.43M | -48.4M | -49.76M | -50.52M | -44.9M |
| Pretax Margin % | -4.94% | -282.72% | -90.04% | 11.27% | -2004.36% | -127.16% | -3703.49% | -3244.02% | -4282.92% | -7087.75% | -31188.27% | -14165.3% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.04M | -15.53M | -12.77M | 3.25M | -25.3M | -33.77M | -64.81M | -53.43M | -48.4M | -49.76M | -50.52M | -44.9M |
| Net Margin % | -4.94% | -282.72% | -90.04% | 11.27% | -2004.36% | -127.16% | -3703.49% | -3244.02% | -4282.92% | -7087.75% | -31188.27% | -14165.3% |
| Net Income Growth % | 95.88% | 54.01% | 80.3% | 106.09% | 47.73% | 32.14% | -28.28% | -18.98% | -51.55% | -63.17% | -116.04% | -82.63% |
| Net Income (Continuing) | -1.04M | -15.53M | -12.77M | 3.25M | -25.3M | -33.77M | -64.81M | -53.43M | -48.4M | -49.76M | -50.52M | -44.9M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00 | -0.04 | -0.04 | 0.01 | -0.07 | -0.09 | -0.18 | -0.17 | -0.20 | -0.20 | -0.21 | -0.22 |
| EPS Growth % | 96.29% | 52.56% | 80.5% | 105.24% | 65% | 55% | 14.29% | 22.73% | -25% | -25% | -50% | -29.41% |
| EPS (Basic) | -0.00 | -0.04 | -0.04 | 0.01 | -0.07 | -0.09 | -0.18 | -0.17 | -0.20 | -0.20 | -0.21 | -0.22 |
| Diluted Shares Outstanding | 400.24M | 363.43M | 363.4M | 363.57M | 362.07M | 361.49M | 361.49M | 310.84M | 245.39M | 244.93M | 244.93M | 204.78M |
| Basic Shares Outstanding | 400.24M | 363.43M | 363.4M | 363.29M | 362.07M | 361.49M | 361.49M | 310.84M | 245.39M | 244.93M | 244.93M | 204.78M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |